Clinical trial
PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
NCT02288897 is registered in ClinicalTrials.gov with Provectus Biopharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
- Lead sponsor
- Provectus Biopharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- April 30, 2015
- Completion date
- September 30, 2019
- Enrollment
- 20 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.
cutaneous melanoma